WEBSITE BSE:543998 NSE : VALIANTLAB 18 May, 12:50
Market Cap ₹630 Cr.
Stock P/E 93.2
P/B 2.7
Current Price ₹145.1
Book Value ₹ 54.5
Face Value 10
52W High ₹227
Dividend Yield 0%
52W Low ₹ 139.2
Valiant Laboratories Ltd is a dynamic and innovative company at the forefront of scientific research and development. Specializing in cutting-edge biotechnology and pharmaceutical solutions, Valiant Laboratories is dedicated to advancing healthcare and improving the quality of life. With a strong commitment to research, the company focuses on the creation of novel drugs, diagnostic tools, and therapeutic solutions to address some of the most challenging medical conditions. Valiant Laboratories boasts a team of world-class scientists, engineers, and medical professionals who collaborate to push the boundaries of science and technology. The company's state-of-the-art facilities and dedication to rigorous quality control ensure that their products meet the highest standards. Valiant Laboratories is driven by a vision to make groundbreaking advancements in healthcare, ultimately contributing to a healthier and more prosperous world.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) | Sep 2022 | Dec 2022 | Mar 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|---|
| Net Sales | 88 | 71 | 90 | 60 | 41 | 31 |
| Other Income | 1 | 1 | 2 | 3 | 2 | 3 |
| Total Income | 89 | 72 | 92 | 63 | 42 | 33 |
| Total Expenditure | 77 | 61 | 81 | 61 | 47 | 35 |
| Operating Profit | 12 | 11 | 10 | 2 | -5 | -2 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 1 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 12 | 10 | 10 | 1 | -5 | -3 |
| Provision for Tax | 3 | 3 | 2 | 0 | -2 | -1 |
| Profit After Tax | 9 | 8 | 8 | 1 | -4 | -1 |
| Adjustments | 0 | -0 | -0 | -0 | 0 | 0 |
| Profit After Adjustments | 9 | 8 | 8 | 1 | -4 | -1 |
| Adjusted Earnings Per Share | 2.7 | 2.3 | 2.4 | 0.2 | -0.8 | -0.3 |
| #(Fig in Cr.) | Mar 2023 | TTM |
|---|---|---|
| Net Sales | 334 | 222 |
| Other Income | 5 | 10 |
| Total Income | 339 | 230 |
| Total Expenditure | 299 | 224 |
| Operating Profit | 40 | 5 |
| Interest | 0 | 0 |
| Depreciation | 2 | 1 |
| Exceptional Income / Expenses | 0 | 0 |
| Profit Before Tax | 38 | 3 |
| Provision for Tax | 9 | -1 |
| Profit After Tax | 29 | 4 |
| Adjustments | 0 | 0 |
| Profit After Adjustments | 29 | 4 |
| Adjusted Earnings Per Share | 8.9 | 1.5 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 0% | 0% | 0% | 0% |
| Operating Profit CAGR | 0% | 0% | 0% | 0% |
| PAT CAGR | 0% | 0% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | NA% | NA% | NA% | NA% |
| ROE Average | 29% | 29% | 29% | 29% |
| ROCE Average | 24% | 24% | 24% | 24% |
| #(Fig in Cr.) | Mar 2023 |
|---|---|
| Shareholder's Funds | 100 |
| Minority's Interest | 0 |
| Borrowings | 59 |
| Other Non-Current Liabilities | 2 |
| Total Current Liabilities | 51 |
| Total Liabilities | 213 |
| Fixed Assets | 48 |
| Other Non-Current Assets | 14 |
| Total Current Assets | 151 |
| Total Assets | 213 |
| #(Fig in Cr.) | Mar 2023 |
|---|---|
| Opening Cash & Cash Equivalents | 1 |
| Cash Flow from Operating Activities | 56 |
| Cash Flow from Investing Activities | -55 |
| Cash Flow from Financing Activities | -1 |
| Net Cash Inflow / Outflow | -0 |
| Closing Cash & Cash Equivalent | 1 |
| # | Mar 2023 |
|---|---|
| Earnings Per Share (Rs) | 8.91 |
| CEPS(Rs) | 9.39 |
| DPS(Rs) | 0 |
| Book NAV/Share(Rs) | 30.86 |
| Core EBITDA Margin(%) | 10.51 |
| EBIT Margin(%) | 11.5 |
| Pre Tax Margin(%) | 11.42 |
| PAT Margin (%) | 8.68 |
| Cash Profit Margin (%) | 9.15 |
| ROA(%) | 13.62 |
| ROE(%) | 28.86 |
| ROCE(%) | 24.01 |
| Receivable days | 96.81 |
| Inventory Days | 14.26 |
| Payable days | 62.43 |
| PER(x) | 0 |
| Price/Book(x) | 0 |
| Dividend Yield(%) | 0 |
| EV/Net Sales(x) | 0.27 |
| EV/Core EBITDA(x) | 2.27 |
| Net Sales Growth(%) | 0 |
| EBIT Growth(%) | 0 |
| PAT Growth(%) | 0 |
| EPS Growth(%) | 0 |
| Debt/Equity(x) | 0.59 |
| Current Ratio(x) | 2.97 |
| Quick Ratio(x) | 2.71 |
| Interest Cover(x) | 151.14 |
| Total Debt/Mcap(x) | 0 |
| # | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|
| Promoter | 74.94 | 74.94 | 74.94 |
| FII | 8.64 | 7.08 | 3.48 |
| DII | 1.76 | 0.43 | 0 |
| Public | 14.66 | 17.55 | 21.58 |
| Others | 0 | 0 | 0 |
| Total | 100 | 100 | 100 |
| # | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|
| Promoter | 3.26 | 3.26 | 3.26 |
| FII | 0.38 | 0.31 | 0.15 |
| DII | 0.08 | 0.02 | 0 |
| Public | 0.64 | 0.76 | 0.94 |
| Others | 0 | 0 | 0 |
| Total | 4.35 | 4.35 | 4.35 |
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
You May Also Know About
